


Tyrosinase (206-214), human

Cat. No.:	HY-P3813
CAS No.:	166188-11-0
Molecular Formula:	C ₆₁ H ₈₃ N ₁₅ O ₁₀
Molecular Weight:	1186.41
Sequence Shortening:	AFLPWHRLF
Target:	Tyrosinase
Pathway:	Metabolic Enzyme/Protease
Storage:	Sealed storage, away from moisture and light, under nitrogen
	Powder -80°C 2 years
	-20°C 1 year



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (105.36 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	0.8429 mL	4.2144 mL	8.4288 mL	
		5 mM	0.1686 mL	0.8429 mL	1.6858 mL	
		10 mM	0.0843 mL	0.4214 mL	0.8429 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (1.75 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (1.75 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (1.75 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) ^[1] .
In Vitro	Tyrosinase (206-214), human (AFLPWHRLF) can be used to generate melanoma-specific T cells for adoptive immunotherapy, as well as in peptide vaccines for HLA-A24 ⁺ melanoma ^[1] .

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Tyrosinase (206-214) is administered intranasally (i.n.; 45 µL; weekly for three weeks) into HLA-A24 transgenic (A24Tg) mice. Tyrosinase (206-214) shows an accumulation of murine CD3 ⁺ and CD8 ⁺ cells around the bronchioles. All A24Tg immunized with Tyrosinase (206-214) died after lethal A/HK483 infection ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. X Kang, et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol. 1995 Aug 1;155(3):1343-8.
- [2]. Toru Ichihashi, et al. Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model. PLoS One. 2011;6(9):e24626.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA